cas 122536-76-9|| where to buy (S)-3-(Boc-amino)pyrrolidine

Название продукции:(S)-3-(Boc-amino)pyrrolidine

IUPAC Name:tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate

Упаковочная единица	Доступно для заказа	Цена ($)
CM102456-25g	in stock	ƥƈ
CM102456-100g	in stock	ǙǙĲ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Дополнительные примечания

Verification code*

refresh

: Номер CAS:122536-76-9; Молекулярная формула:C9H18N2O2; Точка плавления:-; Smiles-код:O=C(N[C@@H]1CNCC1)OC(C)(C)C; Плотность:

: Номер в каталоге:CM102456; Молекулярная масса:186.26; Точка кипения:; Номер Mdl:MFCD00143194; Хранение:Store at room temperature.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: Vorolanib; EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.